Analysis Quality & compliance

FDA closes Dr. Reddy's Bachupally FTO-3 inspection as VAI: what it means

Dr. Reddy's says the US regulator classified its Hyderabad formulations plant as Voluntary Action Indicated and closed the inspection. The details behind the label are not public in the record.

VigiEye editorial · Tue 17 Nov 2026

What happened

Dr. Reddy's Laboratories says the US Food and Drug Administration has classified its inspection of the Bachupally FTO-3 formulations plant in Hyderabad as Voluntary Action Indicated (VAI). The company also says the agency considers the inspection officially closed. The information comes from the company's own disclosure filed with the US Securities and Exchange Commission.

The record does not say when the inspection took place, how long it ran, or how many observations were issued. It does not say what those observations covered or which products are made at the site. It also does not include any FDA statement. Everything here rests on the company's account of the agency's decision.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →